Abiopharma

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Companys technology platform, a patented and validated state-of-the-art 3D cell expansion system, enables the development of novel cell-based solutions to address some of the worlds most pressing challenges-from medicine and climate change to food scarcity and animal welfare. Pluris platform is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. The Company operates in the regenerative medicine, foodtech, and agtech sectors and also provides Contract Development and Manufacturing Organization (CDMO) services. Through strategic partnerships, Pluri aims to deploy its proprietary 3D cell-based technology across industries that demand effective and scalable cell production.

Additional info from NASDAQ:
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global well-being and sustainability. The Companys technology platform, a patented and validated state-of-the-art 3D cell expansion system, enables the development of novel cell-based solutions to address some of the worlds most pressing challenges-from medicine and climate change to food scarcity and animal welfare. Pluris platform is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. The Company operates in the regenerative medicine, foodtech, and agtech sectors and also provides Contract Development and Manufacturing Organization (CDMO) services. Through strategic partnerships, Pluri aims to deploy its proprietary 3D cell-based technology across industries that demand effective and scalable cell production.